Management of PID

← Back to Index (🦠 Infectious Diseases)

General Principles of Management

Infection Mitigation and Precautions

Precautionary measures to reduce or minimize exposure to infection must be tailored to the severity of the primary immune deficiency disease (PID).
Patients with severe immunologic defects, such as severe combined immunodeficiency (SCID), benefit from strict isolation.
Universal precautions, including proper and thorough hand hygiene, must be frequently practiced by patients and their close contacts.
The use of masks covering the nose and mouth is recommended to avoid highly transmissible infections, particularly for patients awaiting immune reconstitution following a hematopoietic stem cell transplant (HSCT) or those currently on immunosuppressive medications.
Clinicians should maintain a low threshold for utilizing diagnostic testing to identify acute infections early and initiate aggressive antimicrobial therapy.

Immunization Guidelines

Immunization with live viral or bacterial vaccines (e.g., oral polio virus, rotavirus, adenovirus, smallpox, typhoid, yellow fever, measles-mumps-rubella [MMR], varicella, and bacille Calmette-Guérin [BCG]) is strictly contraindicated in patients with complete cellular immune defects, such as SCID or complete DiGeorge syndrome.
Patients receiving immunoglobulin G (IgG) replacement therapy (IgRT) do not require routine vaccinations because they receive passive immunization from the products, which provide protective antibodies against tetanus, diphtheria, measles, varicella, pertussis, and pneumococci.
Household members and close contacts should receive all recommended vaccines, including MMR, varicella, and annual influenza vaccines, to facilitate herd immunity, but they should avoid live oral polio and live influenza vaccines to prevent viral shedding.
Administration of IgRT may interfere with vaccination efficacy because the provided antibodies can bind vaccine antigens and inhibit the host immune response; consequently, an 8-month waiting period after the last intravenous immunoglobulin (IVIG) infusion is recommended before administering live vaccines.
For COVID-19, vaccination with non-live vaccines is highly recommended, and high-risk immunocompromised patients should receive additional doses per updated public health guidelines.

Antimicrobial Prophylaxis

Cellular and Combined Immunodeficiencies

In patients with SCID, immediate antimicrobial prophylaxis is directed toward Pneumocystis jiroveci pneumonia (PJP) using a combination of sulfamethoxazole and trimethoprim (TMP-SMX).
In infants younger than 2 months, alternatives for PJP prophylaxis such as atovaquone, dapsone, or pentamidine are considered to avoid bilirubin displacement and the subsequent risk of kernicterus.
Prophylaxis in SCID may also include fluconazole to prevent mucocutaneous candidiasis, acyclovir for viral prophylaxis, and palivizumab during respiratory syncytial virus (RSV) season for children under 2 years of age.
In endemic regions where the BCG vaccine is given at birth, daily chemoprophylaxis with isoniazid and rifampin is necessary until definitive treatment with HSCT due to the high risk of disseminated BCG infection.
Patients with hyper-IgM syndrome or CD40 ligand deficiency require PJP prophylaxis and must avoid contaminated water and recreational water parks to prevent Cryptosporidium parvum infection, which can trigger severe sclerosing cholangitis.
Wiskott-Aldrich syndrome management often incorporates prophylactic antimicrobials against PJP and herpes simplex virus (HSV), along with lifelong penicillin prophylaxis if a splenectomy is performed for refractory thrombocytopenia.
Patients with STAT3 hyper-IgE (Job) syndrome require TMP-SMX prophylaxis against Staphylococcus aureus and Streptococcus pneumoniae, alongside antifungal prophylaxis with itraconazole to prevent Aspergillus and Candida infections.

Innate and Phagocytic Immunodeficiencies

Chronic granulomatous disease (CGD) patients require lifelong prophylaxis with TMP-SMX for bacterial pathogens (e.g., S. aureus, Serratia marcescens, Burkholderia cepacia) and itraconazole to prevent invasive Aspergillus infections.
Leukocyte adhesion deficiency (LAD) necessitates antibiotic prophylaxis to protect against S. aureus and gram-negative bacilli.
Patients with interferon-gamma/interleukin-12 (IFN-y/IL-12) pathway defects (Mendelian susceptibility to mycobacterial diseases) require daily prophylaxis with azithromycin or clarithromycin to prevent nontuberculous mycobacteria (NTM) and Salmonella infections.
Severe viral susceptibility disorders (e.g., STAT1 or STAT2 deficiency, TLR3 deficiency) benefit from targeted antiviral prophylaxis (e.g., acyclovir or valacyclovir) and rigorous avoidance of live viral vaccinations.

Humoral and Complement Immunodeficiencies

Predominantly antibody deficiencies, such as common variable immunodeficiency (CVID), may benefit from long-term macrolide antibiotics (e.g., azithromycin) in conjunction with IgRT, which reduces exacerbations and mitigates the development of bronchiectasis.
Terminal complement pathway deficiencies predispose patients to severe recurrent neisserial infections, requiring prophylactic penicillin and strict adherence to pneumococcal, Haemophilus influenzae, and meningococcal immunizations.

Immunoglobulin Replacement Therapy (IgRT)

Indications and Efficacy

IgRT is the primary treatment for immunodeficiencies characterized by absent or deficient antibody production, including X-linked agammaglobulinemia (XLA), CVID, and specific antibody deficiency.
Initiation of IgRT reduces both acute and chronic infections; maintaining IgG trough levels above 800 mg/dL prevents serious bacterial illnesses and enteroviral meningoencephalitis, while levels up to 1,000 mg/dL may further reduce the risk of pneumonia.

Products, Dosing, and Administration

Human immunoglobulin preparations can be administered intravenously (IVIG) or subcutaneously (SCIG) and provide passive immunity via preformed antibodies against a wide range of pathogens.
For IVIG, maintenance therapy is typically initiated at 400 to 600 mg/kg every 3 to 4 weeks.
For traditional SCIG, a starting dose of 100 to 200 mg/kg of body weight per week is commonly used, providing more flexibility for daily, weekly, or biweekly administration.
Facilitated SCIG (fSCIG) uses recombinant human hyaluronidase to allow large-volume subcutaneous administrations (400 to 600 mg/kg) via one or two sites every 3 to 4 weeks, matching the interval convenience of IVIG while maintaining stable trough levels.
When converting a patient from IVIG to SCIG, area under the curve (AUC) dose adjustments are sometimes applied, requiring 1.37 times the IVIG dose for 16% SCIG products and 1.53 times for 20% products, though in clinical practice this adjustment is rarely strictly utilized.
The ultimate goal of IgRT dosing is not to achieve a specific absolute IgG level, but rather to maximize clinical outcomes and keep the patient relatively infection-free.

Adverse Reactions and Premedication

Most IVIG adverse reactions are rate-related and occur in 5 to 15 percent of infusions; these can usually be managed by slowing or temporarily stopping the infusion.
Premedication regimens for IVIG include oral acetaminophen or ibuprofen, diphenhydramine, and/or oral or intravenous corticosteroids.
Severe allergic reactions, including anaphylaxis, can rarely occur in IgA-deficient patients who possess IgE anti-IgA antibodies.
For patients with severe IgA-mediated reactions to IVIG, utilizing low-IgA IVIG formulations or transitioning to SCIG (which is highly tolerated without anaphylaxis) is recommended.

Curative Therapies

Hematopoietic Stem Cell Transplantation (HSCT)

Allogeneic HSCT is the definitive and potentially curative treatment for numerous PIDs, including SCID, hyper-IgM syndrome, LAD, Wiskott-Aldrich syndrome, and CGD.
For SCID, HSCT performed in the first 100 days of life, prior to the onset of opportunistic infections, achieves a survival rate of 95 percent.
Infants with SCID who lack residual natural killer (NK) activity or maternal T-cell engraftment can sometimes receive HSCT without any preceding myeloablative conditioning regimen.
Donors are typically selected using high-resolution molecular typing; an HLA-identical sibling is the preferred donor, offering the highest probability of survival.
If an HLA-matched sibling is unavailable, options include matched unrelated volunteers, full-haplotype mismatched family members, and unrelated umbilical cord blood donors.
To reduce the risk of acute and chronic graft-versus-host disease (GVHD) in mismatched or unrelated donor transplants, T-cell depletion of the graft (ex vivo) or in vivo prophylaxis (such as posttransplant cyclophosphamide) is routinely employed.
Selective graft manipulation techniques, such as the specific depletion of alpha/beta T cells and B lymphocytes, preserve gamma/delta T cells and NK cells, conferring protection against infections while minimizing GVHD.
GVHD presents acutely (2 to 8 weeks post-HSCT) with maculopapular rash, vomiting, diarrhea, and hyperbilirubinemia; it is primarily treated with systemic corticosteroids.
Steroid-refractory GVHD management incorporates ruxolitinib (a Janus kinase inhibitor), extracorporeal photopheresis, mesenchymal stromal cells, or biologics targeting tumor necrosis factor (TNF) and interleukin-6 (IL-6).

Gene Therapy and Enzyme Replacement

Gene therapy utilizing lentiviral vectors has demonstrated clinical recovery and long-term immune reconstitution in trials for ADA-SCID, X-linked SCID, X-linked CGD, and Wiskott-Aldrich syndrome.
Lentiviral vectors have largely replaced early retroviral vectors, significantly reducing the risk of insertional mutagenesis and secondary leukoproliferative complications.
In patients with adenosine deaminase (ADA) deficiency, enzyme replacement therapy using polyethylene glycol-modified ADA (PEG-ADA) can provide temporary immune restoration, although HSCT or gene therapy provides more robust and definitive correction.

Targeted and Immunomodulatory Therapies

Management of Tregopathies and Immune Dysregulation

Immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome is initially managed with immunosuppressants such as cyclosporine, tacrolimus, or sirolimus in conjunction with corticosteroids as a bridge to curative HSCT.
CTLA4 haploinsufficiency and LRBA deficiency, which cause enteropathy, autoimmune cytopenias, and lymphoproliferation, are successfully treated with abatacept or belatacept (CTLA4-Ig fusion proteins) and sirolimus.
STAT1 and STAT3 gain-of-function variants present with pronounced multiorgan autoimmunity and inflammation, which can be therapeutically targeted using Janus kinase inhibitors (Jakinibs) such as ruxolitinib.
Autoimmune lymphoproliferative syndrome (ALPS) features defective lymphocyte apoptosis and massive lymphadenopathy; it is managed with mycophenolate mofetil or mTOR inhibitors like sirolimus (rapamycin) to control adenopathy and cytopenias.
Primary hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory emergency requiring prompt treatment with corticosteroids, cytotoxic chemotherapy (etoposide), and immunomodulators to reduce disease activity prior to definitive HSCT.

Management of Other Specific Pathways

Chronic Granulomatous Disease (CGD): In addition to antimicrobials, prophylactic administration of subcutaneous interferon-gamma (50 mcg/m2 three times per week) significantly reduces the frequency of hospitalizations and severe infections, and corticosteroids are utilized in short pulses to manage obstructive granulomatous inflammation.
STAT1 Gain-of-Function (CMC): Chronic mucocutaneous candidiasis requires aggressive antifungal therapy, but voriconazole should be strictly avoided due to a heightened risk of secondary squamous cell skin cancers in these patients.
Hereditary Angioedema (C1-INH Deficiency): Long-term prophylaxis utilizes intravenous or subcutaneous plasma-derived C1-INH concentrate, lanadelumab (a monoclonal antibody inhibiting plasma kallikrein), or berotralstat (an oral kallikrein inhibitor).
Acute attacks of hereditary angioedema are treated on-demand with purified plasma-derived or recombinant C1-INH products, ecallantide (a kallikrein inhibitor), or icatibant (a bradykinin type 2 receptor antagonist).